Cancer Deaths Dropped 34%… Here’s What Most People Don’t Know

Cancer cases are still rising…

But cancer deaths have dropped 34% since 1991 — preventing millions of deaths.

So what changed?

In this episode, we break down cancer epidemiology — the hidden system of data, registries, and research that reveals who gets cancer, why it happens, and how we prevent it at scale.

From risk factors like smoking to screening programs and health disparities, this is the science quietly shaping the fight against cancer.

👉 Enjoyed the episode? Follow the show to get new episodes automatically.

If you found the content helpful, consider leaving a rating or review—it helps support the podcast.

For business and sponsorship inquiries, email us at:
📧 contact@bjanalytics.com

Youtube: https://www.youtube.com/@BJANALYTICS

Instagram: https://www.instagram.com/bjanalyticsconsulting/

Twitter/X: https://x.com/BJANALYTICS

Threads: https://www.threads.com/@bjanalyticsconsulting

Transcript

SPEAKER_01 0:00

In 2026, roughly 2.1 million Americans are going to be diagnosed with cancer, which, well, it sounds like this completely unavoidable storm.

SPEAKER_00 0:09

Absolutely. It's a terrifying number.

SPEAKER_01 0:10

But here is the number that actually matters. Since 1991, the cancer death rate in the US has permitted by 34%. And that massive drop has saved, I mean, an estimated 4.8 million lives.

SPEAKER_00 0:24

It's just an incredible public health victory. And, you know, it was really engineered by a field that rarely ever gets the spotlight, which is cancer epidemiology.

SPEAKER_01 0:32

Right. And so that is our mission for today's deep dive. We're looking at the systematic data collection and the pattern recognition that powers this whole fight.

SPEAKER_00 0:40

Aaron Powell Because if doctors are the infantry fighting this battle, you know, one patient at a time, epidemiologists are really the generals in the watchtower. They're looking at the satellite imagery to see exactly where the enemy is massing.

SPEAKER_01 0:50

Aaron Powell Okay, let's unpack this. Because to understand how those deaths actually dropped, we have to look at how we track that enemy. It's like a national census, but specifically designed to track rogue cells.

SPEAKER_00 1:00

Aaron Powell That's a great way to put it. That watchtower is built on massive national registries. So you have programs like the ISEER program from the National Cancer Institute, which gathers standardized data on uh about 48% of the U.S.

SPEAKER_01 1:15

nearly half the country in one database.

SPEAKER_00 1:17

Aaron Powell And then you had the CDC's National Program of Cancer Registries, the NPCR. And together they form this near-complete longitudinal timeline of almost every diagnosis.

SPEAKER_01 1:26

Aaron Powell So it basically gives us the big picture. I mean, without that massive invisible ledger, we wouldn't even know that we recently hit a huge milestone, which is a 70% overall five-year survival rate.

SPEAKER_00 1:37

The data literally plots out exactly where we are winning.

SPEAKER_01 1:40

But having the data is one thing, right? Like using it to actually intervene is another.

SPEAKER_00 1:44

But it plots out how to win, too. I mean, look back at the 1950s. Epidemiologists tracked thousands of people over years in these massive cohort studies.

SPEAKER_01 1:52

Oh, right. The tobacco studies.

SPEAKER_00 1:54

That data definitively proved the link between tobacco and lung cancer, which ended up driving the smoking declines that largely fuel that 34% drop in mortality we see today.

SPEAKER_01 2:05

But you know, I'm looking at this and getting a little confused. We just praised data for helping us prevent cancer and catch it early. But the sources we're reviewing actually warn against too much screening. Isn't catching cancer early like always a good thing? Find it early.

SPEAKER_00 2:20

You'd think so. But what's fascinating here is this counterintuitive concept called overdiagnosis. It happens when screening detects these really slow-growing clusters of cells that actually never would have caused harm in the patient's lifetime.

SPEAKER_01 2:35

Oh wow. So finding it doesn't automatically mean we need to fight it.

SPEAKER_00 2:38

Exactly. Because treating it can sometimes cause way more trauma than the disease itself ever would have.

SPEAKER_01 2:44

That makes sense. And I saw another term in the research, lead time bias. It's like, imagine starting a race timer 10 minutes early. The runner didn't actually run any faster. You just started the clock sooner.

SPEAKER_00 2:55

That is the perfect way to visualize it. A screening test might shift the time of diagnosis earlier, but it doesn't actually change the final outcome.

SPEAKER_01 3:03

So we aren't extending their life.

SPEAKER_00 3:05

We are just extending the time they know they are sick. So epidemiologists have to constantly crunch this registry data to ensure tools like, you know, mammograms or colonoscopies are actually extending lifespans, not just shifting the timer.

SPEAKER_01 3:18

It really forces us to be honest about what interventions actually work. But looking at the latest registry data, despite all those historical wins, the generals in the watchtower are seeing some pretty alarming new battlefronts.

SPEAKER_00 3:31

We really are. We're seeing some severe disparities in the data now.

SPEAKER_01 3:34

Like how colorectal and breast cancer rates are actively rising in adults under 50.

SPEAKER_00 3:39

Yes. And beyond age, mortality rates for Native American populations are two to three times higher than for white populations across several different cancer types.

SPEAKER_01 3:48

And looking at the research, that disparity is heavily rooted in social determinants, isn't it?

SPEAKER_00 3:53

Absolutely. It's things like lack of access to screening, differing health care quality, and just heavier exposure to environmental risks. The data really forces us to quantify these gaps so we can figure out how to close them.

SPEAKER_01 4:04

Well, here's where it gets really interesting because data science is stepping in to completely change how we track those environmental risks today.

SPEAKER_00 4:12

Oh, it's a total paradigm shift. We are no longer just relying on static databases and clipboards. Machine learning is really taking over.

SPEAKER_01 4:18

Right, like natural language processing or NLP.

SPEAKER_00 4:21

Instead of humans having to manually read through thousands of pathology reports, NLP algorithms can just instantly read all those messy handwritten doctors' notes. Precisely. And then they can take those patterns and use geospatial analysis.

SPEAKER_01 4:40

Which is basically taking a digital map of all these newly discovered cancer cases and overlaying it onto maps of environmental hazards.

SPEAKER_00 4:48

Like chemical spills or polluted groundwater. And the AI can instantly spot exactly where they intersect.

SPEAKER_01 4:54

That is amazing.

SPEAKER_00 4:56

It transforms epidemiology from this historical record into a real-time tracking system. I mean, it is the invisible infrastructure behind every single screening policy and prevention recommendation you rely on.

SPEAKER_01 5:07

Which leaves you with a really fascinating question to ponder.

SPEAKER_00 5:10

Oh, what's that?

SPEAKER_01 5:12

Well, if geospatial mapping and AI become hyper-accurate at predicting exactly where cancer clusters will form based on the local environment and exposures, how long until epidemiological forecasting dictates where you decide to buy your next house or whether you accept a job in a specific city?

SPEAKER_00 5:28

That is a very intense thing to think about.

SPEAKER_01 5:31

So the next time you hear a massive cancer survival statistic, just remember the invisible data ledger that actually made it possible.